Medical Doctor Program year 2025 Reported 2020–2025 Source: CMS Open Payments, 2026 publication

Matthew George

Vascular Surgery Rockford, IL Medical Doctor

NPI 1821484601 CMS profile 8801745

5666 E State St, Ste A, Rockford, IL 61108

Open in the dashboard

General payments

$14,752

53 records reported · program years 2020–2025

Research payments

$0

Paid to them · None reported · program years 2020–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Matthew George of Rockford, IL is reported in the CMS Open Payments database as having received $14,752 across 53 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 76th percentile of Vascular Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,517 17
2024 General $2,574 29
2023 General $507 3
2022 General $154 2
2021 General $5,000 1
2020 General $5,000 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Matthew George
  • Vascular Surgery median
  • Middle half of Vascular Surgery
  • National median

In program year 2025, general payments to Matthew George were reported at $1,517. Among 3,991 Vascular Surgery profiles paid that year, the median was $924 and the middle half received between $273 and $2,636.

Show as a table
Year Matthew George Vascular Surgery median Middle half National median
2019 $0 $796 $226–$2,363 $163
2020 $5,000 $348 $118–$1,110 $114
2021 $5,000 $471 $158–$1,421 $132
2022 $154 $725 $222–$2,183 $149
2023 $507 $836 $257–$2,440 $160
2024 $2,574 $909 $252–$2,619 $164
2025 $1,517 $924 $273–$2,636 $169

Breakdown

Who paid General payments · program years 2020–2025
  1. Medtronic, Inc. $7,900 32 payments
  2. Medtronic Vascular, Inc. $5,000 1 payment
  3. Bard Peripheral Vascular, Inc. $679 4 payments
  4. Abbott Laboratories $285 2 payments
  5. W. L. Gore & Associates, Inc. $255 3 payments
  6. Inari Medical, Inc. $220 3 payments
  7. Boston Scientific Corporation $132 1 payment
  8. Silk Road Medical, Inc. $110 1 payment
  9. Kerecis Limited $49 1 payment
  10. Integra LifeSciences Corporation $33 1 payment
  11. Other $89 4 payments

Every payment, record by record

What the payments were for General payments · program years 2020–2025
  1. Grant $10,000 2 payments
  2. Travel and Lodging $2,494 15 payments
  3. Food and Beverage $2,258 36 payments
Products named General payments · program years 2020–2025
  1. Valiant Navion $5,000 1 payment
  2. Endurant $5,000 1 payment
  3. VENASEAL $1,416 16 payments
  4. Valiant Captivia $1,257 12 payments
  5. RotarexS 6 F x 135 cm $679 4 payments
  6. ESPRIT $285 2 payments
  7. FLOWTRIEVER CATHETER, S $220 3 payments
  8. CT THROMBECTOMY SYSTEM KIT $220 3 payments
  9. ENDURANT IIS $205 2 payments
  10. GORE VIABAHN VBX Balloon Expandable Endo $181 2 payments
  11. Other $1,167 21 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 4 drugs

Part D claims

181

Median for Vascular Surgery: 122

Drug cost

$18,305

Median for Vascular Surgery: $14,135

Branded share of claims

37%

Median for Vascular Surgery: 71%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 13 $16,553
Atorvastatin Calcium Generic 89 $813
Clopidogrel Clopidogrel Bisulfate Brand 54 $684
Rosuvastatin Calcium Generic 25 $256

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,087 Part D prescribers listed as Vascular Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 98 billing codes

Paid by Medicare

$86,812

Medicare's payments for the services billed

Medicare patients

246

Average age 74

Services billed

633

112 women, 134 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 60%
Diabetes 53%
Ischemic heart disease 52%
Chronic kidney disease 51%
Heart failure 44%
COPD 37%
Atrial fibrillation 32%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

53 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record